- Home
- KNSA vs SUPN Comparison
KNSA vs SUPN Comparison
Compare KNSA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | SUPN |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.9B |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | KNSA | SUPN |
|---|---|---|
| Price | $38.58 | $51.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $51.33 | ★ $61.60 |
| AVG Volume (30 Days) | 510.1K | ★ 622.2K |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $597,973,000.00 | ★ $681,539,000.00 |
| Revenue This Year | $61.60 | $8.32 |
| Revenue Next Year | $29.82 | $23.36 |
| P/E Ratio | $88.08 | ★ N/A |
| Revenue Growth | ★ 55.68 | 4.54 |
| 52 Week Low | $17.82 | $29.16 |
| 52 Week High | $44.42 | $57.65 |
Technical Indicators
Market Signals| Indicator | KNSA | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | 63.18 |
| Support Level | $39.16 | $47.80 |
| Resistance Level | $43.00 | $52.50 |
| Average True Range (ATR) | 1.70 | 1.42 |
| MACD | -0.29 | 0.03 |
| Stochastic Oscillator | 6.41 | 77.02 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.